植物大麻素作为新型SGLT2调节剂,用于治疗2型糖尿病的脏葡萄糖再吸收
Raymond Rubianto Tjandrawinata1,2, Dante Saksono Harbuwono3,4, Sidartawan Soegondo3,5
1Center for Pharmaceutical and Nutraceutical Research and Policy, Faculty of Biotechnology, Atma Jaya Catholic University of Indonesia, Jakarta 12930, Indonesia.
Pharmaceuticals (Basel, Switzerland)
|August 28, 2025
概括
植物大麻素通过影响SGLT2来治疗2型糖尿病,提供超出血糖控制的代谢益处. 需要进一步的研究来优化输送并确认临床使用的安全性.
科学领域:
- 药理学
- 代谢疾病
- 自然产品
背景情况:
- 在2型糖尿病 (T2DM) 中,-葡萄糖携带体2 (SGLT2) 抑制剂是有效的,但具有局限性.
- 来自Cannabis sativa的植物性大麻素具有与SGLT2潜在相互作用的多目标药理学.
研究的目的:
- 探索植物大麻素作为新型SGLT2调节剂.
- 将它们的疗效和安全性与合成SGLT2抑制剂进行比较.
主要方法:
- 对SGLT2功能和植物大麻素药理学的叙述性综述.
- 在接,在体外测试,在体内动物模型.
- 试点临床研究和病例报告的分析.
主要成果:
- 在研究中,植物性大麻素与SGLT2的高亲和度结合.
- 在体内研究显示THCV和CBD的降血糖和器官保护作用.
- 试验数据表明THCV可以改善血糖控制,但没有精神作用.
结论:
- 通过潜在的SGLT2调节和代谢益处,植物性大麻素对T2DM管理具有前景.
- 挑战包括低生物可用性,多药性和有限的临床数据.
- 未来的研究需要药物动力学优化和大规模的临床试验.
相关概念视频
Glucagon-like Receptor Agonists
416
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
416
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
255
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
255
Oral Hypoglycemic Agents: Biguanides and Glitazones
288
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
288
Glucose Transporters
24.1K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
24.1K
Oral Hypoglycemic Agents: Glinides
256
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
256
Secondary Active Transport
7.6K
One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme "pump" embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
7.6K


